Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704

Yaacov R. Lawrence, Jennifer Moughan, Anthony M. Magliocco, Alexander C. Klimowicz, William F. Regine, Rex B. Mowat, Thomas A. DiPetrillo, William Small, Jeffry P. Simko, Talia Golan, Kathryn A. Winter, Chandan Guha, Christopher H. Crane, Adam P. Dicker

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

BACKGROUND: The majority of patients with pancreatic cancer who undergo curative resection experience rapid disease recurrence. In previous small studies, high expression of the mismatch-repair protein mutL protein homolog 1 (MLH1) in pancreatic cancers was associated with better outcomes. The objective of this study was to validate the association between MLH1 expression and survival in patients who underwent resection of pancreatic cancer and received adjuvant chemoradiation. METHODS: Samples were obtained from the NRG Oncology Radiation Therapy Oncology Group 9704 prospective, randomized trial (clinicaltrials.gov identifier NCT00003216), which compared 2 adjuvant protocols in patients with pancreatic cancer who underwent resection. Tissue microarrays were prepared from formalin-fixed, paraffin-embedded, resected tumor tissues. MLH1 expression was quantified using fluorescence immunohistochemistry and automated quantitative analysis, and expression was dichotomized above and below the median value. RESULTS: Immunohistochemical staining was successfully performed on 117 patients for MLH1 (60 and 57 patients from the 2 arms). The characteristics of the participants who had tissue samples available were similar to those of the trial population as a whole. At the time of analysis, 84% of participants had died, with a median survival of 17 months. Elevated MLH1 expression levels in tumor nuclei were significantly correlated with longer disease-free and overall survival in each arm individually and in both arms combined. Two-year overall survival was 16% in patients who had low MLH1 expression levels and 53% in those who had high MLH1 expression levels (P <.0001 for both arms combined). This association remained true on a multivariate analysis that allowed for lymph node status (hazard ratio, 0.41; 95% confidence interval, 0.27-0.63; P <.0001). CONCLUSIONS: In the current sample, MLH1 expression was correlated with long-term survival. Further studies should assess whether MLH1 expression predicts which patients with localized pancreatic cancer may benefit most from aggressive, multimodality treatment. Cancer 2018;124:491-8.

Original languageEnglish (US)
Pages (from-to)491-498
Number of pages8
JournalCancer
Volume124
Issue number3
DOIs
StatePublished - Feb 1 2018

    Fingerprint

Keywords

  • adjuvant
  • adjuvant
  • biomarkers
  • chemotherapy
  • clinical trial phase 3
  • mutL protein homolog 1 (MLH1)
  • pancreatic neoplasms
  • radiotherapy
  • tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lawrence, Y. R., Moughan, J., Magliocco, A. M., Klimowicz, A. C., Regine, W. F., Mowat, R. B., DiPetrillo, T. A., Small, W., Simko, J. P., Golan, T., Winter, K. A., Guha, C., Crane, C. H., & Dicker, A. P. (2018). Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer, 124(3), 491-498. https://doi.org/10.1002/cncr.31058